Biopharmaceutical News and Research

RSS
Wyeth Pharmaceuticals to acquire Haptogen

Wyeth Pharmaceuticals to acquire Haptogen

Blood protein detects lung cancer, even at earliest stage

Blood protein detects lung cancer, even at earliest stage

New green methods for coating drugs in plastics

New green methods for coating drugs in plastics

New drugs to combat bioterrorism

New drugs to combat bioterrorism

New strategy for treating allergic disorders

New strategy for treating allergic disorders

Schering-Plough announces licensing of Acadesine

Schering-Plough announces licensing of Acadesine

Cancer survivors share their advice in new book

Cancer survivors share their advice in new book

Roche and Alnylam form RNAi therapeutics alliance

Roche and Alnylam form RNAi therapeutics alliance

Experimental Alzheimer's drug begins clinical trials

Experimental Alzheimer's drug begins clinical trials

Arpida receives FDA approval to initiate Phase II trial with intravenous iclaprim

Arpida receives FDA approval to initiate Phase II trial with intravenous iclaprim

Iloperidone shows promise for Akathisia

Iloperidone shows promise for Akathisia

Ulcerative colitis disruptive in relationships

Ulcerative colitis disruptive in relationships

Smokeless cannabis-vaporizing device may help those with HIV-related neuropathy

Smokeless cannabis-vaporizing device may help those with HIV-related neuropathy

New treatment for warts

New treatment for warts

Sigma-Aldrich acquires Molecular Medicine BioServices

Sigma-Aldrich acquires Molecular Medicine BioServices

New system for restoring damaged or lost knee cartilage tissue

New system for restoring damaged or lost knee cartilage tissue

Chitin compound causes allergic inflammation

Chitin compound causes allergic inflammation

Purdue molecule could lead to first drug treatment for Alzheimer's disease

Purdue molecule could lead to first drug treatment for Alzheimer's disease

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Use of computer-assisted drug design in drug discovery

Use of computer-assisted drug design in drug discovery

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.